MARIA BEATRIZ CAMARGO MONTEIRO CAILLAUD

(Fonte: Lattes)
Índice h a partir de 2011
9
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
LIM/18 - Laboratório de Carboidratos e Radioimunoensaios, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2018 ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 11 Citação(ões) na Scopus
    Dietary advanced glycated end-products and medicines influence the expression of SIRT1 and DDOST in peripheral mononuclear cells from long-term type 1 diabetes patients
    (2018) SANTOS-BEZERRA, Daniele P.; MACHADO-LIMA, Adriana; MONTEIRO, Maria Beatriz; ADMONI, Sharon N.; PEREZ, Ricardo V.; MACHADO, Cleide G.; SHIMIZU, Maria Heloiza; CAVALEIRO, Ana M.; THIEME, Karina; QUEIROZ, Marcia S.; MACHADO, Ubiratan F.; GIANNELLA-NETO, Daniel; PASSARELLI, Marisa; CORREA-GIANNELLA, Maria Lucia
    Quantitative polymerase chain reaction was employed to quantify expression of two genes coding for advanced glycation end-product receptors [RAGE (AGER) and AGER1 (DDOST)] and of the gene coding the deacetylase SIRT1 (SIRT1) in peripheral blood mononuclear cells from type 1 diabetes patients without [Group A, n = 35; 28.5 (24-39) years old; median (interquartile interval)] or with at least one microvascular complication [Group B, n = 117; 34.5 (30-42) years old]; 31 healthy controls were also included. In a subgroup of 48 patients, daily advanced glycation end-products intake before blood collection was assessed. Lower expression of DDOST was found in patients than in controls after adjustment for sex, age, use of statins, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Higher expressions of AGER, DDOST and SIRT1 were observed in Group A. Stratifying by complications, AGER and DDOST expressions were higher in those without retinopathy and without diabetic kidney disease, respectively, compared to patients with these complications. Patients using statins or angiotensin receptor blockers presented higher expression of DDOST. Expression of SIRT1 was higher in patients consuming >= 12,872 KU daily of advanced glycation end-products. Although AGER, DDOST and SIRT1 are differently expressed in peripheral blood mononuclear cells from type 1 diabetes patients with and without microvascular complications, they are also influenced by dietary advanced glycation end-products and by statins and angiotensin receptor blockers.
  • article 29 Citação(ões) na Scopus
    Gain-of-function variants in NLRP1 protect against the development of diabetic kidney disease: NLRP1 inflammasome role in metabolic stress sensing?
    (2018) SOARES, Jaine L. S.; FERNANDES, Fernanda Pereira; PATENTE, Thiago Andrade; MONTEIRO, Maria B.; PARISI, Maria C.; GIANNELLA-NETO, Daniel; CORREA-GIANNELLA, Maria L.; PONTILLO, Alessandra
    Although inflammasome plays a well-known role in animal models of renal injury, limited studies in humans are available, and its participation in diabetic kidney disease (DKD) remains unknown. Aim of this study was to elucidate the contribution of inflammasome genetics in the development of DKD in type-1 diabetes (T1D). The association of functional variants in inflammasome genes with DKD was assessed by multivariate analysis in a retrospective and in a prospective cohort. NLRP1 rs2670660 and rs11651270 polymorphisms were significantly associated with a decrease risk to develop DKD (p(adj) < 0.01), and rs11651270 also with a lower risk of new renal events during follow-up (p(adj) = 0.01). Supporting these findings, diabetes metabolites (glycated albumin and high glucose) were able to modulate NLRP1 expression. This study is the first to suggest a protective role of NLRP1 in DKD, highlighting an emerging role of NLRP1 as a homeostatic factor against metabolic stress.